Trial reportChinese medical journal2026
Systolic blood pressure time-in-target range and kidney outcomes in patients with hypertension: Findings from the STEP trial.
Trial report in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03015311 (Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTime-in-target range (TTR) of systolic blood pressure (SBP) is determined by the proportion of time during which the SBP remains within a defined optimal range. The study aims to explore the association between SBP TTR and the occurrence of chronic kidney disease (CKD) in hypertensive patients.
methodsA post hoc analysis of data from the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial was performed. The STEP trial compared intensive (110 to <130 mmHg) and standard (130 to <150 mmHg) SBP interventions in hypertensive individuals. The SBP TTR was calculated from baseline to 6 months using 110-130 mmHg and 130-150 mmHg as the target ranges for the intensive and standard groups, respectively. The primary outcome for this study was the first occurrence of CKD (estimated glomerular filtration rate <60 mL·min -1 ·1.73m -2 ). Cox proportional regression models were used to assess the association between SBP TTR and renal outcomes.
resultsOverall, 4924 participants were included in this study. Participants with a higher SBP TTR were likely to have a higher baseline diastolic blood pressure. In fully adjusted models, a 1-standard deviation increase in SBP TTR was associated with a 10% lower risk of poor kidney outcomes (hazard ratio [HR], 0.90; 95% confidence interval [CI], 0.83-0.98). Compared with participants in the lowest TTR group (T1: 0 to <38%), those in the highest TTR tertile (T3: 81% to <100%) had a lower risk of renal outcomes (HR: 0.76; 95% CI: 0.61-0.94). Sensitivity analysis showed consistent results when considering the competing risk of death and a combined target range of 110-140 mmHg for SBP.
conclusionsA higher SBP TTR was associated with a lower risk of kidney events in adults with hypertension. Therefore, the SBP TTR may be considered a potential therapeutic target and quality metric. REGISTRATION: No. NCT03015311 at ClinicalTrials.gov.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.